Allergan's sales of eye care pharmaceuticals rose by 6.6 percent year-on-year to $603.4 million in the fourth quarter of 2010. At constant currency rates, turnover was up by 7.4 percent. The company's overall revenues rose by 6.9 percent, or by 7.4 percent on a currency-neutral basis, and reached $1.29 billion. Group net income improved to $263.1 million in the quarter against $222.8 million a year earlier. In the full year, Allergan's sales of eye care pharmaceuticals were up by 7.7 percent to $2.26 billion, or 7.4 percent higher at constant currency rates. Group sales increased to $4.82 billion from $4.45 billion. Net income for the year was $4.9 million, down sharply from $623.8 million in 2009.